Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye. Blade has assembled scientific and leadership teams with unparalleled experience. Our scientific team as well as our Board have extensive expertise in fibrosis and the discovery and development of anti-fibrotic drugs. Blade’s scientific advisory board includes world renowned experts in the pathobiology of fibrotic disease. By targeting novel pathways common to multiple fibrotic disease states, we believe we can build the leading company in anti-fibrotic drug discovery and development.